Eligible placebo controlled trials
| Study protocol number | Pain condition(s) included | No of participants assigned to gabapentin and placebo | Daily dose in each gabapentin group |
| 945-21020 | Diabetic neuropathic pain | 165 | Maximum (target) dose 3600 mg |
| 945-22421 | Diabetic neuropathic pain | 325 | Fixed doses 600, 1200 and 2400 mg/day |
| 945-400-21122–24 | Postherpetic neuralgia | 229 | Fixed dose 3600 mg/day |
| 945-430-29525 | Postherpetic neuralgia | 334 | Fixed doses 1800 and 2400 mg/day |
| 945-430-30626 | Neuropathic pain (Allowed: complex regional pain syndrome or reflex sympathetic dystrophy; pain because of traumatic injury; diabetic peripheral neuropathy; phantom limb pain or pain following amputation of limbs; post-herpetic neuralgia; radicular pain or radiculopathy associated with spinal stenosis; stroke) | 305 | Maximum (target) dose 2400 mg |
| A945-100827 | Diabetic peripheral neuropathy | 389 | Maximum (target) dose 3600 mg |